Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | MAOB | P27338 | 3/20 | 0.66 |
| ▸ | MAOA | P21397 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | IDO1 | P14902 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alcohol SCHEMBL28251587 | 0.93 | MAPT (0.64) | HPGDCYP1A2CYP2C19MAOBMAOA | |
| SCHEMBL8167087 | 0.88 | CYP1A2 (0.85) | HPGDCYP1A2CYP2C19MAOBMAOA | |
| SCHEMBL9386726 | 0.86 | KMT2A (0.71) | HPGDMAPTALDH1A1GAAMEN1 | |
| SCHEMBL27938794 | 0.85 | HPGD (0.66) | HPGDCYP1A2CYP2C19MAOBMAOA | |
| SCHEMBL455344 | 0.83 | IDO1 (0.78) | MAPTALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL12177297 | 0.82 | HPGD (1.00) | HPGDCYP1A2CYP2C19MAOBMAOA | |
| SCHEMBL1884695 | 0.82 | MAOB (0.73) | HPGDCYP1A2CYP2C19MAOBMAOA | |
| SCHEMBL457063 | 0.81 | MAPT (0.63) | HPGDCYP1A2CYP2C19MAPTALDH1A1 | |
| SCHEMBL1259295 | 0.81 | CYP1A2 (1.00) | HPGDCYP1A2CYP2C19MAOBMAOA | |
| SCHEMBL18031168 | 0.81 | CYP1A2 (0.73) | HPGDCYP1A2CYP2C19MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111454232-A | 1,3, 4-thiadiazine compound and application thereof | 南方医科大学 | 2020-07-28 | — | — | CN | claimed |
| WO-2016111658-A1 | SYNTHESIS OF THIOSEMICARBAZONE DERIVATIVES COMPRISING SULPHONAMIDE GROUP WITH POTENTIAL ANTICONVULSANT ACTIVITY | IYIDOGAN AYSEGUL (TR) | 2016-07-14 | — | — | WO | claimed |
| CN-122010896-A | Bicyclol derivative, pharmaceutical composition thereof, preparation method and application thereof | 中国医学科学院药物研究所 | 2026-05-12 | — | — | CN | disclosed |
| WO-2025087819-A1 | CATALYST AND METHOD FOR PRODUCING HYDROGEN BY PROTON REDUCTION | RENER (FR) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025046420-A1 | COMPOUND TARGETING EGR-1 AND USE THEREOF FOR TREATMENT OF ATOPIC DERMATITIS | 주식회사 아제라메디 | 2025-03-06 | — | — | WO | disclosed |
| CN-114634502-B | 3-Aryl substituted thiazolidine-4-ketone-2-methylene hydrazono methylene-1H-indole derivative and preparation method thereof | 复旦大学 | 2024-05-24 | — | — | CN | disclosed |
| CN-114634502-A | 3-aryl substituted thiazolidine-4-ketone-2-ylidenehydrazonomethylene-1H-indole derivatives and preparation method thereof | 复旦大学 | 2022-06-17 | — | — | CN | disclosed |
| WO-2022086079-A1 | DERIVATIVE OF SEMICARBAZONE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | 고려대학교 산학협력단 | 2022-04-28 | — | — | WO | disclosed |
| CN-111454232-B | 1,3, 4-thiadiazine compound and application thereof | 南方医科大学 | 2021-11-23 | — | — | CN | disclosed |
| US-20210276964-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | CEDARS SINAI MEDICAL CENTER (US) | 2021-09-09 | — | — | US | disclosed |
| US-10836735-B2 | Compositions and methods for treating cancers | CEDARS-SINAI MEDICAL CENTER (US) | 2020-11-17 | — | — | US | disclosed |
| US-20080269218-A1 | Novel Hsp90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269218-A1 | Novel Hsp90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2008-10-30 | — | — | US | disclosed |
| US-5506236-A | TREATING HERPES VIRUS INFECTIONS | SCHERING CORPORATION | 1996-04-09 | — | — | US | disclosed |
| US-4268680-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-05-19 | — | — | US | disclosed |
| US-4244964-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-01-13 | — | — | US | disclosed |
| US-4232034-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 1980-11-04 | — | — | US | disclosed |
| US-4229581-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-10-21 | — | — | US | disclosed |
| US-4229460-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-10-21 | — | — | US | disclosed |
| US-4160841-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 1979-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836735-B2 | Compositions and methods for treating cancers | HDAC3, HDAC1, GSK3B | HPGD 1439/4885CYP1A2 3443/4885CYP2C19 3944/4885 |
| US-20080269218-A1 | Novel Hsp90 Inhibitor | HSP90AB1, HSP90AB2P, HSP90B1 | HPGD 1183/4885CYP1A2 1815/4885CYP2C19 2108/4885 |
| US-20210276964-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | HDAC3, HDAC1, GSK3B | HPGD 1439/4885CYP1A2 3443/4885CYP2C19 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.